Herantis Pharma: Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act
Company release
Herantis Pharma Plc, Company release, 18 February 2025 at 16:00 p.m. EET
Herantis Pharma: Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act
Herantis Pharma Plc (“Herantis”) has, on 18 February 2025, received a notification from Kyösti Kakkonen in accordance with chapter 9, section 10 of the Securities Market Act. According to the notification, holdings of Kyösti Kakkonen in Herantis have on 17 February 2025 decreased below 10 per cent. Kyösti Kakkonen's holdings in Herantis have diluted below the 10 per cent threshold due to remaining shares issued in the share issue announced by Herantis on 6 February 2025 having been registered with the trade register on 17 February 2025.
Herantis has one series of shares in which each share carries one vote. The percentages and numbers indicate the shareholding on the date of the notification received by Herantis.
| Total positions of Kyösti Kakkonen subject to the notification obligation: | ||||
| % of shares and voting rights (total of 7.A) | % of shares and voting rights through financial instruments (total of 7.B) | Total of both in % (7.A + 7.B) | Total number of shares and voting rights of issuer | |
| Resulting situation on the date on which threshold was crossed or reached | 9.7905952 | 9.7905952 | 24,094,817 | |
| Position of previous notification (if applicable) | 10.7467968 | 10.7467968 | 20,160,733 | |
| Notified details of the resulting situation on the date on which the threshold was crossed or reached: | ||||
| A: Shares and voting rights | ||||
Class/type of shares ISIN code (if possible) | Number of shares and voting rights | % of shares and voting rights | ||
Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
| FI4000087861 | 2,359,026 | 9.7905952 | ||
| SUBTOTAL A | 2,359,026 | 9.7905952 | ||
| Information in relation to the person subject to the notification obligation | |||
| Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer. | |||
| Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity: | |||
| Name | % of shares and voting rights | % of shares and voting rights through financial instruments | Total of both |
| Kyösti Kakkonen | 0.087156 | 0 | 0.087156 |
| K22 Finance Oy* | 0.912794 | 0 | 0.912794 |
| Joensuun Kauppa ja Kone Oy** | 8.7906457 | 0 | 8.7906457 |
*Kyösti Kakkonen holds 77.78 per cent of K22 Finance Oy.
**Kyösti Kakkonen holds 55.3 per cent of Kakkonen-Yhtiöt Oy, which holds 100 per cent of Joensuun Kauppa ja Kone Oy.
For more information, please contact:
Tone Kvåle, CFO
Tel: +47 915 19576
Email: ir@herantis.com
Certified Advisor:
UB Corporate Finance Ltd
Tel.: +358 9 25 380 225
E-mail: ubcf@unitedbankers.fi
About Herantis Pharma Plc
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. The primary aim of the ongoing Phase 1b clinical trial is to show that repeated subcutaneous doses of HER-096 are safe and well-tolerated in patients with Parkinson’s disease. The Phase 1a clinical trial, completed in late 2023, demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in healthy volunteers.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Company website: www.herantis.com